Sign In
Buy XERS
$5.89
-0.110 (-1.83%)
At Close: Jun 03, 2026
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
11:15am, Thursday, 20'th Mar 2025
Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more str
Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript
10:52am, Thursday, 06'th Mar 2025
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings
10:30am, Thursday, 06'th Mar 2025
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with W
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
09:15am, Thursday, 06'th Mar 2025
Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago.
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:05am, Wednesday, 26'th Feb 2025
Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
08:00am, Monday, 24'th Feb 2025
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON,
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
07:00am, Friday, 10'th Jan 2025
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announce
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:15pm, Monday, 06'th Jan 2025
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
07:00am, Tuesday, 26'th Nov 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript
11:50am, Friday, 08'th Nov 2024
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Of
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:30am, Friday, 08'th Nov 2024
While the top- and bottom-line numbers for Xeris Biopharma (XERS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metri
Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates
09:10am, Friday, 08'th Nov 2024
Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago.
Xeris Biopharma Reports Third Quarter 2024 Financial Results
07:00am, Friday, 08'th Nov 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
08:00am, Thursday, 31'st Oct 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
